Which of the following is a method of pharmacotherapy for post-gastric bypass hypoglycemia?

Diazoxide is a medication that can be effectively used to manage post-gastric bypass hypoglycemia, particularly because of its ability to inhibit insulin secretion from the pancreas. In individuals who have undergone gastric bypass surgery, symptoms of reactive hypoglycemia can occur due to rapid changes in blood glucose levels after meals. Diazoxide helps to stabilize these levels by decreasing insulin release, which in turn can decrease the occurrence of hypoglycemic episodes.

This approach is particularly relevant in the context of post-operative patients who may demonstrate heightened insulin sensitivity and altered glucose metabolism after surgery. As a result, diazoxide serves as a useful pharmacological intervention for addressing the challenges of reactive hypoglycemia in this population.